nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP2J2—Fatty acids—CYP2A7—nicotine dependence	0.0874	0.243	CbGpPWpGaD
Rivaroxaban—CYP2J2—Xenobiotics—CYP2A7—nicotine dependence	0.0694	0.193	CbGpPWpGaD
Rivaroxaban—Toothache—Varenicline—nicotine dependence	0.0386	0.062	CcSEcCtD
Rivaroxaban—Menorrhagia—Varenicline—nicotine dependence	0.0318	0.0509	CcSEcCtD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0288	0.0803	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0284	0.0792	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0234	0.0651	CbGpPWpGaD
Rivaroxaban—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.02	0.0557	CbGpPWpGaD
Rivaroxaban—Renal failure acute—Varenicline—nicotine dependence	0.0185	0.0296	CcSEcCtD
Rivaroxaban—Osteoarthritis—Varenicline—nicotine dependence	0.0171	0.0274	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.0171	0.0274	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Varenicline—nicotine dependence	0.0156	0.025	CcSEcCtD
Rivaroxaban—Angina pectoris—Varenicline—nicotine dependence	0.0144	0.023	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0132	0.0367	CbGpPWpGaD
Rivaroxaban—Infestation—Varenicline—nicotine dependence	0.0132	0.0211	CcSEcCtD
Rivaroxaban—Infestation NOS—Varenicline—nicotine dependence	0.0132	0.0211	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.013	0.0209	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Varenicline—nicotine dependence	0.0124	0.0199	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—CYP2A7—nicotine dependence	0.0124	0.0346	CbGpPWpGaD
Rivaroxaban—Epistaxis—Varenicline—nicotine dependence	0.0124	0.0199	CcSEcCtD
Rivaroxaban—Sinusitis—Varenicline—nicotine dependence	0.0123	0.0198	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0122	0.0341	CbGpPWpGaD
Rivaroxaban—Urinary tract disorder—Varenicline—nicotine dependence	0.0117	0.0187	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Varenicline—nicotine dependence	0.0116	0.0186	CcSEcCtD
Rivaroxaban—Urethral disorder—Varenicline—nicotine dependence	0.0116	0.0186	CcSEcCtD
Rivaroxaban—Erythema multiforme—Varenicline—nicotine dependence	0.0112	0.0179	CcSEcCtD
Rivaroxaban—Eye disorder—Varenicline—nicotine dependence	0.011	0.0177	CcSEcCtD
Rivaroxaban—Cardiac disorder—Varenicline—nicotine dependence	0.011	0.0176	CcSEcCtD
Rivaroxaban—Angiopathy—Varenicline—nicotine dependence	0.0107	0.0172	CcSEcCtD
Rivaroxaban—Immune system disorder—Varenicline—nicotine dependence	0.0107	0.0171	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Varenicline—nicotine dependence	0.0106	0.0171	CcSEcCtD
Rivaroxaban—Back pain—Varenicline—nicotine dependence	0.00994	0.0159	CcSEcCtD
Rivaroxaban—Muscle spasms—Varenicline—nicotine dependence	0.00988	0.0158	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Varenicline—nicotine dependence	0.00954	0.0153	CcSEcCtD
Rivaroxaban—Anaemia—Varenicline—nicotine dependence	0.0095	0.0152	CcSEcCtD
Rivaroxaban—Angioedema—Varenicline—nicotine dependence	0.00939	0.0151	CcSEcCtD
Rivaroxaban—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.0093	0.0259	CbGpPWpGaD
Rivaroxaban—Malaise—Varenicline—nicotine dependence	0.00927	0.0149	CcSEcCtD
Rivaroxaban—Syncope—Varenicline—nicotine dependence	0.00922	0.0148	CcSEcCtD
Rivaroxaban—Loss of consciousness—Varenicline—nicotine dependence	0.00903	0.0145	CcSEcCtD
Rivaroxaban—Chest pain—Varenicline—nicotine dependence	0.00875	0.014	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00869	0.0139	CcSEcCtD
Rivaroxaban—Discomfort—Varenicline—nicotine dependence	0.00865	0.0139	CcSEcCtD
Rivaroxaban—Dry mouth—Varenicline—nicotine dependence	0.00856	0.0137	CcSEcCtD
Rivaroxaban—Oedema—Varenicline—nicotine dependence	0.00839	0.0135	CcSEcCtD
Rivaroxaban—Infection—Varenicline—nicotine dependence	0.00833	0.0134	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00831	0.0231	CbGpPWpGaD
Rivaroxaban—Shock—Varenicline—nicotine dependence	0.00825	0.0132	CcSEcCtD
Rivaroxaban—Nervous system disorder—Varenicline—nicotine dependence	0.00823	0.0132	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0082	0.0228	CbGpPWpGaD
Rivaroxaban—Tachycardia—Varenicline—nicotine dependence	0.00819	0.0131	CcSEcCtD
Rivaroxaban—Skin disorder—Varenicline—nicotine dependence	0.00815	0.0131	CcSEcCtD
Rivaroxaban—Hypotension—Varenicline—nicotine dependence	0.00784	0.0126	CcSEcCtD
Rivaroxaban—Dyspnoea—Varenicline—nicotine dependence	0.00748	0.012	CcSEcCtD
Rivaroxaban—Dyspepsia—Varenicline—nicotine dependence	0.00738	0.0118	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00724	0.0116	CcSEcCtD
Rivaroxaban—Fatigue—Varenicline—nicotine dependence	0.00723	0.0116	CcSEcCtD
Rivaroxaban—Constipation—Varenicline—nicotine dependence	0.00717	0.0115	CcSEcCtD
Rivaroxaban—Pain—Varenicline—nicotine dependence	0.00717	0.0115	CcSEcCtD
Rivaroxaban—Feeling abnormal—Varenicline—nicotine dependence	0.00691	0.0111	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Varenicline—nicotine dependence	0.00686	0.011	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00673	0.0188	CbGpPWpGaD
Rivaroxaban—Urticaria—Varenicline—nicotine dependence	0.00666	0.0107	CcSEcCtD
Rivaroxaban—Abdominal pain—Varenicline—nicotine dependence	0.00663	0.0106	CcSEcCtD
Rivaroxaban—Hypersensitivity—Varenicline—nicotine dependence	0.00618	0.00991	CcSEcCtD
Rivaroxaban—Asthenia—Varenicline—nicotine dependence	0.00602	0.00965	CcSEcCtD
Rivaroxaban—Pruritus—Varenicline—nicotine dependence	0.00593	0.00952	CcSEcCtD
Rivaroxaban—Diarrhoea—Varenicline—nicotine dependence	0.00574	0.0092	CcSEcCtD
Rivaroxaban—Dizziness—Varenicline—nicotine dependence	0.00555	0.0089	CcSEcCtD
Rivaroxaban—F10—cardiovascular system—nicotine dependence	0.00542	0.311	CbGeAlD
Rivaroxaban—Vomiting—Varenicline—nicotine dependence	0.00533	0.00855	CcSEcCtD
Rivaroxaban—Rash—Varenicline—nicotine dependence	0.00529	0.00848	CcSEcCtD
Rivaroxaban—Dermatitis—Varenicline—nicotine dependence	0.00528	0.00847	CcSEcCtD
Rivaroxaban—Headache—Varenicline—nicotine dependence	0.00525	0.00843	CcSEcCtD
Rivaroxaban—Nausea—Varenicline—nicotine dependence	0.00498	0.00799	CcSEcCtD
Rivaroxaban—CYP2J2—cardiovascular system—nicotine dependence	0.00444	0.255	CbGeAlD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00386	0.0108	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00381	0.0106	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00379	0.0106	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00358	0.00996	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00353	0.00983	CbGpPWpGaD
Rivaroxaban—CYP2J2—midbrain—nicotine dependence	0.00347	0.199	CbGeAlD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00313	0.00872	CbGpPWpGaD
Rivaroxaban—CYP2J2—brain—nicotine dependence	0.00218	0.125	CbGeAlD
Rivaroxaban—CYP2J2—Metabolism—CYP2A7—nicotine dependence	0.00212	0.00591	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00176	0.00491	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.00166	0.00463	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00164	0.00457	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000986	0.00275	CbGpPWpGaD
Rivaroxaban—ABCB1—cardiovascular system—nicotine dependence	0.00083	0.0477	CbGeAlD
Rivaroxaban—ABCB1—midbrain—nicotine dependence	0.000649	0.0373	CbGeAlD
Rivaroxaban—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000612	0.0017	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000462	0.00129	CbGpPWpGaD
Rivaroxaban—ABCB1—brain—nicotine dependence	0.000408	0.0234	CbGeAlD
Rivaroxaban—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000284	0.000792	CbGpPWpGaD
